From Medscape Oncology

Coverage From The

American Society of Hematology (ASH) 2018

December 01 - 05, 2018; San Diego, California

December 01 - 05, 2018 San Diego, California

Conference News

Popular News from ASH 2017

  • Top News From ASH 2017: Slideshow Top News From ASH 2017: Slideshow Hot topics include moving to newer oral anticoagulants for cancer patients with VTE, plus practice-changing results in chronic lymphocytic leukemia, multiple myeloma, and Hodgkin's lymphoma.
  • Oral Agents for Cancer-Related VTE: 'New Standard of Care' Oral Agents for Cancer-Related VTE: 'New Standard of Care' The oral agent rivaroxaban was as effective as subcutaneous dalteparin in controlling VTE in patients with cancer but was associated with a higher rate of bleeding.
  • Mastocytosis Becomes a 'Disease You Don't Want to Miss' Mastocytosis Becomes a 'Disease You Don't Want to Miss' A novel drug designed specifically to target a mutation found in 90% of cases shows marked activity, and has already sparked an increase in interest in this disease.

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage